If your SUD practice runs definitive (confirmation) drug testing and 80%+ of your screens are billing as G0480, you’re under-coding the work. The G0480 to G0483 series is stratified by complexity (number of drug classes tested), and the reimbursement delta between G0480 and G0483 can be 4-5x per claim.
For a residential SUD program running 100 confirmation panels per month, the difference between mostly G0480 and properly-stratified billing is $80-150K in annual revenue. That’s not a billing error pattern. That’s a configuration default you can fix in your practice management system in 30 minutes. Here’s what’s actually happening, and how to fix it.
The G0480-G0483 stratification — exactly how it works
The HCPCS codes for definitive (LC-MS/MS, GC-MS) drug testing are stratified by drug classes tested per specimen: G0480 covers 1-7 drug classes including metabolites per date of service. G0481 covers 8-14 drug classes. G0482 covers 15-21 drug classes. G0483 covers 22 or more drug classes.
The “drug class” count is what the LAB tested, not what the panel ordered. If your panel tests 22 different drug classes (opioids + benzodiazepines + cocaine + amphetamines + cannabinoids + barbiturates + buprenorphine + methadone + alcohol metabolites + synthetic opioids + designer drugs + etc.), the appropriate code is G0483, not G0480.
National Medicare allowables (CY 2025, approximate): G0480 ~$87, G0481 ~$117, G0482 ~$155, G0483 ~$215 per claim. Commercial payer rates vary but the ratio is similar. A 22-class panel billing G0480 at $87 instead of G0483 at $215 is a $128 per-claim revenue leak.
Why SUD practices are systematically under-coding
Pattern 1: Practice management system defaults
Most PM systems were set up years ago with G0480 as the default drug screen code. The biller picks it from a dropdown. No one updates the default when the lab adds drug classes to the panel. The fix: check your panel configuration with the lab, then update your PM system’s default code OR build logic that maps panel-by-panel to the correct code.
Pattern 2: Lab reports drug classes — biller doesn’t read them
The lab report lists every drug class tested. The biller’s workflow is “submit drug screen claim” without parsing the report. They use the default code. The fix: standardize on a single confirmation panel per program type (residential vs IOP vs OP), document the exact drug-class count, and code it consistently.
Pattern 3: Risk aversion (“higher codes get audited”)
Some billing teams under-code intentionally because they’ve heard G0483 attracts audit attention. This is real but overstated. CMS does audit drug testing — the audit pattern is documentation-driven, not code-driven. Properly documented G0483 claims survive audit. Properly documented G0480 claims also survive audit. The issue is documentation, not the code itself.
Auditors look for: medical necessity documented in clinical record, order from a treating provider, lab report showing the actual drug classes tested, and patient-specific justification (treatment plan, ongoing monitoring). If your documentation is clean, code to the actual complexity. Under-coding “to avoid audit” is leaving money on the table for nothing.
The audit your practice should run this week
Pull the last 90 days of definitive drug screen claims. For each: What code was billed (G0480/G0481/G0482/G0483)? How many drug classes were tested per the lab report? Were they congruent?
If 80%+ of your screens billed G0480 but your panel tests 15-22 classes, you have a systematic miscoding pattern. The recovery: for claims still within payer correction windows (typically 12 months for Medicare, 90 days for commercial), submit corrected claims with the appropriate code. For claims outside correction windows: not recoverable, but stop the bleeding by fixing the workflow going forward.
Presumptive vs definitive — don’t confuse the categories
There’s a parallel CPT code stratification for presumptive (cup test, immunoassay, point-of-care) drug screens: 80305 for direct optical observation, 80306 read by instrument, 80307 chemistry analyzer. Reimbursement is much lower (~$20-50 per claim) because presumptive testing is less complex. These are the cup tests done at intake.
Definitive testing (G0480-G0483) is the LC-MS/MS confirmation done at a reference lab, ordered when presumptive results need confirmation or when forensic-grade documentation is required for treatment compliance. A typical SUD billing workflow: intake with presumptive screen (80305-80307), confirmation sent to reference lab (G0480-G0483), periodic monitoring depending on clinical protocol. Confusing these categories costs revenue both ways.
Documentation requirements for compliant billing
Every G0480-G0483 claim should have: an order from treating provider specifying the test, medical necessity, and patient identifier (standing orders for “all SUD patients” don’t satisfy this); a lab report naming the specific drug classes tested with measured concentrations; clinical justification in the patient record (why this test was ordered: treatment monitoring, compliance verification, suspected use, transition between phases); and a treatment plan reference tying periodic testing to documented milestones.
Payer-specific traps
State Medicaid programs — many states cap drug screen frequency per patient per quarter or year. Exceeding the cap = denial even with proper coding.
Commercial payers — Aetna, BCBS plans often require prior authorization for definitive testing beyond a certain frequency. Failing to obtain PA = denial.
Quantitative reporting — some payers require specific drug concentrations measured (not just positive/negative). Your lab report should include this.
Bundled IOP/PHP codes — H0015 (IOP per diem) bundles certain services. Whether drug testing is bundled vs separately reportable depends on the payer.
The reimbursement-recovery math
For a residential SUD program with 100 patients running confirmation testing every 2 weeks: 100 patients × 2 tests/month = 200 confirmation tests/month. If 80% bill G0480 at $87 = $13,920/month. If 80% should be G0483 at $215 = $34,400/month. Monthly leak: $20,480. Annual: $245,760.
For an outpatient SUD program with 250 patients on monthly confirmation: 250 tests/month, 80% G0480 instead of G0482 ($155) = $13,600/month leak. Annual: $163,200.
SUD programs running real confirmation testing are usually under-coding by enough to fund a senior staff position annually.
How Revenant Care handles G0480-G0483 coding for SUD clients
We audit drug screen coding as part of our standard SUD denial management process. Our SUD intake workflow includes: 30-day coding audit of last 90 days of definitive drug screen claims, a mapping report (actual code billed vs appropriate code per panel), corrected claims submitted for in-window claims, PM system configuration update, staff training on lab report parsing, and monthly coding accuracy reports ongoing.
Free 30-day denial and coding audit for SUD practices: send us 50-100 claims (denied or paid), we identify miscoded ones and recoverable revenue. You get a report whether or not you become a client.
15-minute scope call: https://calendar.app.google/zF3c44hYGRjEf5U26
FAQs
Q: How do I know which G-code applies to my panel?
A: Ask your reference lab for the drug-class count per panel. Most labs publish a panel composition sheet. Count the unique drug classes tested.
Q: How long do I have to submit corrected claims?
A: Medicare allows 12 months from date of service. Commercial payers typically 90-180 days, varies by plan.
Q: What documentation triggers an audit?
A: High-frequency testing without clinical justification, patterns inconsistent with treatment plan, and prescription monitoring system flags. Code-level audit triggers are less common than documentation-pattern audits.